Research and Clinical Trials
At this time, the APS Foundation of America provides some funding to APS ACTION and other research groups if they request assistance and we have have the funds available.
The following organizations are currently doing research on APS or related diseases. We encourage anyone who qualifies to participate in these clinical studies. By doing so, you could potentially help APS patients in the future!
APS ACTION Hydroxychloroquine Study (1)
Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
aPL-positive patients with no history of thrombosis or other systemic autoimmune diseases are randomized to receive hydroxychloroquine or no treatment in addition to their standard regimen. The study involves 11 study visits and 10 phone visits over 5 years.
APS ACTION aPL/APS Registry (2)
Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
Any aPL-positive patient is included in this clinical database and repository. The study involves 11 study visits and 10 phone visits over 10 years.
Microbiome Study (3)
Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY
Contact:
Joann Vega
(212) 774-2795
aPL-positive patients who are not receiving immunosuppressive treatment is included in this study that seeks to find if any particular intestinal bacteria may trigger aPL production. Participation will involve 3 study visits over a period of 2 months
PROMISSE Study (4)
Principal Investigator:
Dr. Jane Salmon
Hospital for Special Surgery, New York, NY*
Contact:
Anasam Aslam
(212) 774-2115
Pregnant (6-11 weeks preferably, but can usually recruit up to 18 weeks), history of aPL positivity with or without SLE.
AXLN1007 in Antiphospholipid Syndrome (5)
Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
Study Title: An Open-Label Proof of Concept Phase IIa Trial of AXLN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
This is an open-label study where patients will receive 12 doses of study drug over 22 weeks for Non-criteria Manifestations of APS (low platelet count, skin ulcers or abnormal kidney function).
Navigate through Current Clinical Trials using the left and right arrows.
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
This site complies with the HONcode standard for trustworthy health information: verify here.
Information Sheets
DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.